Dunhill Financial’s Rhythm Pharmaceuticals RYTM Stock Holding History

Dunhill Financial’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$65	–	2052
2025 Q4	$65	Buy	+1	New	+$106	﹤0.01%	1562

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Dunhill Financial's RYTM Position: Q1 2026 in Review

Dunhill Financial sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 1 share — an estimated $65 sold.

Dunhill Financial first reported a position in RYTM in Q4 2025 and held it in 1 quarter. The position peaked at $65 in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

Dunhill Financial reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Dunhill Financial sold 1 Rhythm Pharmaceuticals share in Q1 2026, an estimated $65.
Dunhill Financial first reported a position in Rhythm Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Dunhill Financial's Rhythm Pharmaceuticals position peaked at $65 in Q4 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.